Navigation Links
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Date:11/5/2011

ts and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

FORWARD-LOOKING STATEMENTSAll statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the safety and efficacy of KRYSTEXXA, status of our KRYSTEXXA marketing efforts and additional plans related thereto, market demand and reimbursement for KRYSTEXXA, our view of the refractory chronic gout (RCG) market size, and our market expansion plans including our MAA filing before the EMA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, our ability to commercialize KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated;
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
2. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
6. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
7. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
9. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
10. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... On August 31, 2015, United States District ... 123-page order in the first of the consolidated MDL ... replacement devices are defective.[1]  The Court ... Robyn Christiansen,s claims for defective design, fraudulent misrepresentation and ... Medical,s claim that the Medical Device Amendment to the ...
(Date:9/1/2015)... , Sept. 1, 2015  Amgen (NASDAQ: ... Novartis in the areas of Alzheimer,s disease and ... Alzheimer,s disease by teaming up with Novartis on ... directed at genetically predisposed individuals at risk of ... focus on the commercialization of its migraine programs ...
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
Breaking Medicine Technology:Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Relieving Drug Market Analysis 2010-2025 , , , ... , Reports details , ... opportunities lie in this diverse market with high, growing demand worldwide? , , ...
... WESTLAKE VILLAGE, Calif. , May 4 ... provider of specialty physician consultations via telemedicine, announced today ... Organization,s 2010 Innovations in Healthcare ABBY Award.  SOC won ... category for their 24/7 teleneurology service that provides immediate ...
Cached Medicine Technology:Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17Specialists On Call Wins 2010 Innovations in Healthcare ABBY Award 2
(Date:9/1/2015)... ... ... The Journal of Pain Research has published the original research ... corresponding author Mr Christopher Malone says “Migraine headache is a painful chronic condition affecting ... understand how migraine headaches impact the lives of migraineurs. We asked migraineurs about a ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced its annual Light it Red for Lymphoma awareness initiative, the nation’s premier ...
(Date:9/1/2015)... WA (PRWEB) , ... September 01, 2015 , ... Philanthropic ... increasing awareness of societal issues and needs. Money for Good 2015, released today by ... solving it. There’s an annual potential to mobilize up to $22B in new philanthropic ...
(Date:9/1/2015)... Meadows, Ill. (PRWEB) , ... September 01, 2015 ... ... procedures done by members of the American Society for Dermatologic Surgery, according to ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in the ... beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look and ...
Breaking Medicine News(10 mins):Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... extend to youths, behavior as family situations change, study ... might be known for spoiling grandchildren, but a new ... improve their social skills and behavior. , ... help children from single-parent, divorced/separated or stepfamily households, according ...
... Freedom Magazine article on psychiatric screening was awarded the DeRose-Hinkhouse Memorial ... ... Los Angeles, Ca (PRWEB) March 6, 2009 -- Freedom Magazine, a ... the Religion Communicators Council (RCC) with the 2009 DeRose-Hinkhouse Memorial Awards ...
... Huntington Hospital Cancer Center has received the Outstanding ... Surgeons Commission on Cancer (CoC), which recognizes cancer ... care to their patients."This is an extremely important ... staff, hospital staff and administration, to provide the ...
... Mich.---Revered in India as "holy powder," the marigold-colored spice ... treat wounds, infections and other health problems. In recent ... ingredient, curcumin, has burgeoned, as its astonishing array of ... revealed. , Yet little has been known about ...
... March 6 Nu Skin Enterprises, Inc. (NYSE: ... the Bank of America and Merrill Lynch Consumer Conference in ... will be webcast live beginning at 10:05 a.m. (EDT). Those ... page on Nu Skin Enterprises, Web site, at www.nuskinenterprises.com ...
... to fat in liver, which may trigger disease, study says ... PGC-1b appears to play a role in insulin resistance that ... syrup, a sweetener found in most sodas and many processed ... diet were protected from insulin resistance when PGC-1b activity was ...
Cached Medicine News:Health News:In Tough Times, Kids May Find Solace With Grandparents 2Health News:Scientology Magazine Earns Religion Communicators Council Award 2Health News:Huntington Hospital Cancer Center Receives Outstanding Achievement Designation 2Health News:'Holy powder' ingredient makes membranes behave for better health 2Health News:Gene Explains How High-Fructose Diets Lead to Insulin Resistance 2
... disposable loading unit, the LDS-2™ instrument places two ... the cartridge jaw and the knife blade divides ... instrument is activated by squeezing the instrument's handle ... size of the clip is determined by the ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
... LIGACLIP Clip Applier is a reusable instrument ... clips. This instrument is used with LIGACLIP ... either 316L stainless steel or titanium. The ... tubular structures where a nonabsorbable ligating device ...
The Tissue Approximating Forceps are to aid in the approximating of the tissue edges....
Medicine Products: